<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636972</url>
  </required_header>
  <id_info>
    <org_study_id>PPAI-001</org_study_id>
    <nct_id>NCT02636972</nct_id>
  </id_info>
  <brief_title>The Progression From Dysmenorrhoea to Chronic Pelvic Pain</brief_title>
  <official_title>The Progression From Dysmenorrhoea to Chronic Pelvic Pain: Investigation of the Role of Chronic Inflammatory Pain Phenotype in Peripheral Blood as a Potential Biomarker.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional observational study.

      For participants resident in Adelaide, South Australia.

      The study consists of 3 visits to the Pain and Anaesthesia Research Clinic (PARC), within the
      Royal Adelaide Hospital (RAH).

      A total of 56 participants will be recruited for this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve a screening visit followed by two visits to PARC for blood sampling
      and questionnaires.

      At the baseline visit, blood samples to assess biomarkers and confirm hormonal status will be
      taken.

      From screening until the final study visit a total of approximately 120 mL in blood samples
      will be taken from each participant.

      The study aims to further knowledge in the presence of severe pelvic pain in young women
      which is an area that has been under-researched with regard to it's impact on society.

      The study proposes to enroll 7 groups of 8 healthy nulliparous women aged 18-35 with the
      following characteristics:

      Mild or absent dysmenorrhoea (pain scale 0-3) and no other pelvic pain symptoms. (3 groups)

        -  Group 1, without contraceptive pill use

        -  Group 2A , contraceptive pill user and with a history of mild or absent dysmenorrhoea
           prior to pill use

        -  Group 2B, contraceptive pill user and with a history of severe dysmenorrhoea (pain scale
           7-10) prior to pill use

      Severe dysmenorrhoea (pain scale 7-10), but without chronic pelvic pain. (2 groups)

        -  Group 3, without contraceptive pill use

        -  Group 4, contraceptive pill user

      Chronic pelvic pain and severe dysmenorrhoea (2 groups)

        -  Group 5, without contraceptive pill use

        -  Group 6,contraceptive pill user
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reactivity of stimulated isolated peripheral blood immune cells</measure>
    <time_frame>2 weeks</time_frame>
    <description>To determine if there are different inflammatory pain phenotypes between young women with either severe dysmenorrhoea alone, chronic pelvic pain from controls with mild or no dysmenorrhoea from the collected peripheral blood immune cells (assessed by cytokine output).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of pelvic pain on everyday activities using the Pelvic Pain Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Secondary efficacy end point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anxiety and depression using the DAS21</measure>
    <time_frame>2 weeks</time_frame>
    <description>Secondary efficacy end point</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Dysmenorrhoea</condition>
  <condition>Pelvic Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <description>History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <description>History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <description>Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCPs</intervention_name>
    <description>Participants in the contraceptive pill groups can use any one of the following contraceptive pills:
Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra</description>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample retained for future analysis (may include DNA analysis)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Nulliparous women in good general health (can experience dysmenorrhoea (abscent, mild or
        severe), with or without pelvic pain and with or without contraceptive pill use)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 16 to 35 years old

        Exclusion Criteria:

          -  Irregular menstrual cycles

          -  Use of any reproductive hormonal preparations (other than the combined oral
             contraceptive pill), thyroxine, insulin or corticosteroids

          -  Presence of an inflammatory process, or clinically significant infection in the 4
             weeks

          -  Clinically significant renal, hepatic, cardiac, auto-immune disease

          -  Current use of immunosuppressant medication such as hydroxychloroquine, methotrexate
             or azathioprine

          -  Inability to read or comprehend the written information provided

          -  Current use of medications known to affect TLR responsiveness including amitriptyline
             or minocycline

          -  Current use of any analgesics, including non-steroidal anti-inflammatory medications
             and opioids for 5 drug half-lives prior to the day of testing

          -  Current or previous pregnancy

          -  Body Mass index less than 18 or more than 30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Evans, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>PARC Research Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PARC, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>Dr Susan Evans</investigator_full_name>
    <investigator_title>MBBS, FRANZCOG, FFPMANZCA, GAICD</investigator_title>
  </responsible_party>
  <keyword>TLR2</keyword>
  <keyword>TLR4</keyword>
  <keyword>Biomarker</keyword>
  <keyword>TLR responsiveness</keyword>
  <keyword>Peripheral blood responsiveness</keyword>
  <keyword>Inflammatory pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

